In June 2022, at the XXXII Conference of the Italian Society of Parasitology, the parallels of the main endoparasitic infections of horses and donkeys were discussed. Although these 2 species are genetically different, they can be challenged by a similar range of parasites (i.e. small and large strongyles, and Parascaris spp.). Although equids can demonstrate some level of resilience to parasites, they have quite distinct helminth biodiversity, distribution and intensity among different geographical locations and breeds. Heavily infected donkeys may show fewer clinical signs than horses. Although parasite control is primarily provided to horses, we consider that there may be a risk of drug-resistance parasitic infection through passive infection in donkeys when sharing the same pasture areas. Knowing the possible lack of drug efficacy (<90 or 80%), it is advocated the use of selective treatment for both species based on fecal egg counts. Adult horses should receive treatment when the threshold exceeds 200–500 eggs per gram (EPG) of small strongyles. Moreover, considering that there are no precise indications in donkeys, a value >300 EPG may be a safe recommendation. We have highlighted the main points of the discussion including the dynamics of helminth infections between the 2 species.

L’objectif de ce document est de proposer aux médecins du travail des INB, des recommandations pour la rédaction de protocoles de traitement par le Ca-DTPA des contaminations internes par le plutonium et l’américium. Ces recommandations s’appuient sur le bilan des injections réalisées dans les centres CEA et AREVA en France. Elles ont été réalisées par un groupe de travail de médecins du CEA, d’AREVA et du Service de protection radiologique des Armées. Cet article concerne principalement le Ca-DTPA administré par voie intraveineuse (IV). Les autres formes galéniques, voies d’administration ainsi que les traitements adjuvants sont également évoqués. Pour les plaies contaminées et les inhalations, les indications du traitement par le Ca-DTPA sont précisés ; en particulier son initialisation, sa posologie, sa durée, sa fréquence d’administration, les critères d’arrêt, son efficacité et le gain dosimétrique. Une aide décisionnelle est proposée pour la prescription du suivi radiotoxicologique nécessaire à la conduite du traitement et à l’évaluation dosimétrique.

Snoring and Obstructive Sleep Apnea (OSA) are caused by repetitive dynamic closure of the oropharyngeal airway. There exists substantial and growing epidemiologic evidence that OSA is associated with a variety of systemic conditions, including but not limited to, systemic hypertension, stroke, congestive heart failure, increased motor vehicle accidents, impaired quality of living and mortality. There is an equal amount of literature on the use of dental appliances as a treatment modality for OSA. The object of this report is to review the literature in regards to three vital aspects of this disease: a) the etiology and sequela of OSA; b) the dental management of the condition and its mode of action; and lastly, c) the positive and negative outcomes/risks, of dental management.

This study aims to investigate the facilities available in Accident and Emergency (A&E) departments and the education of casualty officers in the treatment of epistaxis in the UK. Fifty departments were chosen at random and a telephone survey undertaken. The results show a paucity of facilities and inadequate training of A&E officers in a majority of departments. Recommendations for treatment standards are made.